A study of management strategy on the price investigation of medicine -A case study of COPD on B Company

• Main Authors: Meng-Chieh Lai, 賴孟傑
• Other Authors: HilaryCheng
• Format: Others
• Language: zh-TW
• Online Access: http://ndltd.ncl.edu.tw/handle/53300422811468432520

碩士 === 元智大學 === 管理碩士在職專班 === 100 === The health insurance for whole citizen renders convenience and health-care since 1995. Due to the continuous new developed medicine, high price medicine and repeat consulting doctor….and so on, those factors resulted in the finance of Health Insurance Bureau encountered obstacles. In addition, it seems quite difficult to increase the fees of health insurance that makes the policy to reduce the price of medicine to deal with decreasing the total amount expense. Accordingly, the investigation of medicine has been carried out since 2000. The 7th adjustment was executed since 1, Dec, 2011. This is no doubt that this is a threaten for new developed medicine company. The company should take advantage on enhancing the competition to maintain the profits and keep the market share. The goal of this study is to analyze the medicine of COPD(Chronic Obstruction Pulmonary Disease) through SWOT. The pros and cons are compared by the exterior opportunity and threaten. Then, the SCP model will be applied to understand the factor the key factor why Spiriva is success. That is, this medicine is the first priority treatment for Doctors to handle the illness of COPD. The strategies among the process are worth for us to understand. It also provides a good reference to associated companies on their plan and management.